Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vafidemstat - Oryzon Genomics

Next Previous
Drug Profile

Vafidemstat - Oryzon Genomics

Alternative Names: ORY-2001

Latest Information Update: 26 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oryzon
  • Developer Institute of Medical and Molecular Genetics; Oryzon
  • Class Amines; Antidementias; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Cyclopropanes; Neuroprotectants; Nootropics; Oxadiazoles; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Aggression; Alzheimer's disease; Borderline personality disorders; Multiple sclerosis; SARS-CoV-2 acute respiratory disease; Schizophrenia
  • No development reported Autistic disorder; Dementia; Huntington's disease; Parkinson's disease; Telomeric 22q13 Monosomy Syndrome

Most Recent Events

  • 23 Jun 2025 Oryzon announces intention to submit an regulatory application to the US FDA for the phase III PORTICO-2 trial in Borderline personality disorder (BPD) in first half of 2025
  • 23 Jun 2025 Oryzon submits an regulatory application to the US FDA for the phase III PORTICO-2 trial in Borderline personality disorder (BPD)
  • 17 Jun 2025 Pharmacodynamics data from the phase IIa ETHERAL trial in mild to moderate Alzheimer’s disease released by Oryzon

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top